| Literature DB >> 26375282 |
Takeshi Nishijima1, Shigeko Yashiro2, Katsuji Teruya3, Yoshimi Kikuchi3, Naomichi Katai2, Shinichi Oka1, Hiroyuki Gatanaga1.
Abstract
OBJECTIVE: To investigate whether routine eye screening by an ophthalmologist in patients with HIV-1 infection is clinically useful.Entities:
Mesh:
Year: 2015 PMID: 26375282 PMCID: PMC4574439 DOI: 10.1371/journal.pone.0136747
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Patient enrollment process.
¶Two patients had both HIV retinopathy and cataract, one had both cataract and diabetic retinopathy, and one had both HIV retinopathy and diabetic retinopathy. CMV: cytomegalovirus.
Baseline characteristics of study patients and those with various ocular diseases.
| Study patients n = 1515 | Any ocular diseases n = 204 | CMV retinitis n = 24 | HIV retinopathy n = 127 | Cataract n = 31 | Ocular syphilis n = 4 | |
|---|---|---|---|---|---|---|
| Ocular symptoms, n (%) | 50 (3) | 27 (13) | 7 (29) | 10 (8) | 10 (32) | 2 (50) |
| Sex (male), n (%) | 1428 (94) | 199 (98) | 24 (100) | 123 (97) | 31 (100) | 4 (100) |
| Age | 36 (30–44) | 42 (36–54) | 42 (34–53) | 40 (36–51) | 63 (44–66) | 37 (34–44) |
| Asian, n (%) | 1456 (96) | 200 (98) | 22 (92) | 124 (99) | 30 (97) | 4 (100) |
| CD4 count (/μl) | 210 (66–353) | 67 (21–168) | 27 (15–71) | 51 (18–91) | 224 (89–323) | 181 (163–499) |
| HIV RNA load (log10/ml) | 4.76 (4.04–5.28) | 5.22 (4.65–5.71) | 5.28 (4.50–5.81) | 5.36 (4.93–5.85) | 4.59 (3.90–5.20) | 4.35 (3.23–5.43) |
| Treatment-naive, n (%) | 1320 (87) | 185 (91) | 21 (88) | 118 (93) | 26 (84) | 4 (100) |
| CMV diseases other than retinitis, n (%) | 17 (1) | 8 (4) | 2 (8) | 6 (5) | 0 | 0 |
| Anti-CMV treatment, n (%) | 36 (2) | 11 (5) | 3 (13) | 7 (6) | 0 | 0 |
| Rapid plasma reagin titer ≥8, n (%) | 210 (14) | 27 (13) | 4 (17) | 14 (11) | 3 (10) | 4 (100) |
| Chemotherapy, n (%) | 14 (1) | 1 (0.1) | 1 (4) | 0 | 0 | 0 |
| Systemic steroid use, n (%) | 157 (10) | 43 (21) | 5 (21) | 34 (27) | 4 (13) | 0 |
| History of AIDS, n (%) | 477 (32) | 125 (61) | 24 (100) | 83 (65) | 10 (32) | 2 (50) |
| Route of transmission | ||||||
| Homosexual contact, n (%) | 1221 (81) | 161 (79) | 18 (75) | 105 (83) | 24 (77) | 3 (75) |
| Heterosexual contact, n (%) | 229 (15) | 32 (16) | 5 (21) | 17 (14) | 4 (13) | 1 (25) |
| Contaminated blood product, n (%) | 11 (1) | 2 (1) | 0 | 1 (1) | 1 (3) | 0 |
| Injection drug, n (%) | 24 (2) | 3 (1.5) | 0 | 1 (1) | 1 (3) | 0 |
| Unknown, n (%) | 30 (2) | 6 (3) | 1 (4) | 3 (2) | 1 (3) | 0 |
| Months between diagnosis of HIV-1 infection and ophthalmologic examination | 1 (0.3–2.6) | NA | NA | NA | NA | NA |
†Median (interquartile range). CMV: cytomegalovirus, NA: not applicable.
Two patients had both HIV retinopathy and cataract.
¶Ocular symptoms were not assessed in five patients because of altered mental status
*Data for the day of diagnosis of HIV-1 infection are missing for 39 patients.
Prevalence of ocular diseases according to CD4 cell count.
| All patients n = 1515 | CD4 <50 /μl n = 308 | CD4 <100 /μl n = 490 | CD4 <200 /μl n = 731 | CD4 ≥200 n = 784 | |
|---|---|---|---|---|---|
| Any ocular diseases | 204 (14) | 81 (26) | 130 (27) | 162 (22) | 42 (5.4) |
| CMV retinitis | 24 (1.6) | 14 (4.5) | 20 (4.1) | 24 (3.3) | 0 |
| HIV retinopathy | 127 (8.4) | 62 (20) | 97 (20) | 111 (15) | 16 (2) |
| Cataract | 31 (2) | 2 (0.6) | 9 (1.8) | 15 (2.1) | 16 (2) |
| Ocular syphilis | 4 (0.3) | 0 | 0 | 3 (0.4) | 1 (0.1) |
Data are numbers (percentages).
CMV: cytomegalovirus
Uni- and multi-variate analyses to estimate the associations of various factors with cytomegalovirus retinitis.
| Crude model | Adjusted model | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P value | Adjusted OR | 95%CI | P value | |
| Ocular symptoms versus no ocular symptoms | 15 | 5.75–37.6 | <0.001 | 13 | 4.59–36.0 | <0.001 |
| Age per 10 year increment | 1.5 | 1.09–2.07 | 0.012 | 1.2 | 0.86–1.77 | 0.26 |
| CD4 count per 100 /μl decrement | 4.3 | 2.07–8.92 | <0.001 | 3.9 | 1.85–8.30 | <0.001 |
| HIV-1 viral load per 1 log10copies/ml increment | 1.5 | 0.96–2.28 | 0.079 | |||
| CMV diseases other than retinitis | 8.9 | 1.93–41.5 | 0.005 | 3.9 | 0.78–19.1 | 0.097 |
| Anti-CMV treatment | 6.3 | 1.79–22.2 | 0.004 | |||
| History of AIDS | 6.7 | 2.66–17.1 | <0.001 | |||
| Antiretroviral therapy | 1.0 | 0.29–3.27 | 0.96 | |||
| Chemotherapy | 4.9 | 0.62–39.4 | 0.13 | |||
| Systemic steroid use | 2.3 | 0.85–6.30 | 0.099 | |||
Variables with p <0.05 in the univariate analysis were incorporated into the multivariate model. Anti-CMV treatment and history of AIDS were not added to the multivariate model because of multicollinearity with CMV diseases other than retinitis and CD4 count, respectively. History of AIDS was not added to the multivariate model because CMV retinitis is one of the AIDS-defining illnesses.
Uni- and multi-variate analyses to estimate the associations of various factors with HIV retinopathy.
| Crude model | Adjusted model | |||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P value | Adjusted OR | 95%CI | P value | |
| Ocular symptoms versus no ocular symptoms | 3.0 | 1.44–6.06 | 0.003 | 2.2 | 0.99–4.76 | 0.052 |
| Age per 10 year increment | 1.5 | 1.31–1.78 | <0.001 | 1.4 | 1.15–1.61 | <0.001 |
| CD4 count per 100 /μl decrement | 2.3 | 1.92–2.84 | <0.001 | 1.7 | 1.36–2.13 | <0.001 |
| HIV-1 viral load per 1 log10copies/ml increment | 2.5 | 1.95–3.17 | <0.001 | 1.6 | 1.20–2.06 | 0.001 |
| History of AIDS | 4.8 | 3.24–6.99 | <0.001 | 1.6 | 0.97–2.57 | 0.064 |
| Antiretroviral therapy | 0.5 | 0.25–0.99 | 0.046 | 0.8 | 0.37–1.83 | 0.63 |
| Systemic steroid use | 3.8 | 2.44–5.81 | <0.001 | 1.2 | 0.71–1.96 | 0.52 |
Variables with p <0.05 in univariate analysis were incorporated into the multivariate model.